BioSpace News Archive

TG Therapeutics, Inc. (NASDAQ: TGTX) today announced the presentation of data from both the ULTIMATE I & II Phase 3 trials and the ENHANCE Phase 3b trial evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the 2023 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) annual meeting, being held in Milan, Italy.

Aviceda Therapeutics, a privately held, late-stage clinical biotech company focused on developing next-generation immunomodulators by harnessing the power of glycobiology to alleviate chronic non-resolving inflammation, announced today the recent presentation of positive data about AVD-104, its lead ophthalmic clinical asset, at the EURETINA congress held in Amsterdam, Netherlands, from October 4–7, 2023.

Care Access announced today the completion of a for-cause Food and Drug Administration (“FDA”) Good Clinical Practices (“GCP”) inspection related to Care Access’s activities on the Pfizer VALOR trial.

Quanta Therapeutics, a privately-held biopharmaceutical company pioneering targeted therapies to treat RAS-driven cancers, announced data from a late-breaking presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics being held October 11-15, 2023, in Boston, Massachusetts.

PMV Pharmaceuticals, Inc. (Nasdaq: PMVP) today announced that it will present updated Phase 1 data from the ongoing Phase 1/2 PYNNACLE study of PC14586 in a late-breaking poster session at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, taking place October 11-15, 2023, in Boston, Massachusetts.

Franklin Mountain Medical announced today that the Dib UltraNav Transseptal Catheter System, which houses a needle and ultrasound in one system for use in atrial transseptal procedures and delivery of catheters, has now been successfully used in 15 human cases, at major cardiology hospitals in Arizona and Minnesota.

Orexo AB, reports top line results after having completed a study evaluating the efficacy of MODIA in combination with sublingual buprenorphine/ naloxone for the treatment of opioid use disorder and reduction in use of illicit opioids.

Shanghai Kehua Bio-engineering Co., Ltd, China’s leading In Vitro Diagnostic company has achieved a significant milestone by becoming the first Chinese company to obtain EU Class D In Vitro Diagnostic Regulation certification for rapid tests.

Almirall S.A., a global biopharmaceutical company focused on medical dermatology, unveiled new data at the European Association of Dermatology and Venereology Congress 2023 that underscores its commitment to advancing the wellbeing of psoriasis patients and their families through treatments and cutting-edge research.

MediWound Ltd., a fully-integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, announced collaboration with 3M Health Care.